Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xalud Therapeutics

Request full access

Discovers, develops, and provides novel treatments for chronic inflammatory diseases that can dramatically improve the health and quality of life for millions of suffering patients

New York City, United StatesFounded 2009Biotech & Life Sciences

About Xalud Therapeutics

Xalud Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neuroinflammatory diseases and inflammatory joint disorders such as osteoarthritis and rheumatoid arthritis. The company specializes in non-opioid gene therapy solutions aimed at alleviating chronic pain by rebalancing pain signals. Xalud's core technology, developed by Dr. Linda Watkins at the University of Colorado, Boulder, targets glial cells to modulate pain pathways effectively. The company primarily serves patients suffering from chronic pain conditions and inflammatory diseases, offering a promising alternative to traditional opioid treatments. Xalud operates in the biopharmaceutical market, leveraging cutting-edge gene therapy techniques to create long-lasting pain relief solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary therapies. Revenue is generated through partnerships, investments, and future sales of approved treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
62.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Aug 2021 $30M $120M PBM Capital Group —
EARLY VCOther financing Mar 2020 $5M $20M Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Xalud Therapeutics website traffic

Latest recorded traffic for Xalud Therapeutics is 1.8K monthly website visits, up 480.6% over the last three months. Xalud Therapeutics's team declined 16.7% over the past year.

Latest monthly visits1.8K 3-month web change+480.6% 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Xalud Therapeutics in the New York City ecosystem

Live from Dealroom

The Xalud Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • US Department of War
  • National Institute of Neurological Disorders and Stroke
  • US Department of Health and Human Services

Series B and later1 investor entered at this stage

  • PBM Capital Group

Other known investors1 additional known investor

  • University of Colorado Boulder
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xalud Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xalud Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.